Ketamine to Treat Patients With Post-comatose Disorders of Consciousness

Phase 2/3 Unknown 30 enrolled University of Liege Centre Hospitalier Universitaire de Liege · collab William Lennox Neurological Center UCLouvain · collab

RandomizedCrossoverTriple-blindTreatment

Summary

The investigators will run a Randomized Clinical Trial with 30 patients with disorders of consciousness (DoC), with intravenous subanesthetic doses of ketamine. Patients will simultaneously undergo TMS-EEG. The piloting will be done on 3 patients, with EEG only.

Timeline

Start: 2022-05-01
Primary completion: 2025-05-01
Completion: 2026-05-01

Publications

Background Casali AG, Gosseries O, Rosanova M, Boly M, Sarasso S, Casali KR, Casarotto S, Bruno MA, Laureys S, Tononi G, Massimini M. A theoretically based index of consciousness independent of sensory processing and behavior. Sci Transl Med. 2013 Aug 14;5(198):198ra105. doi: 10.1126/scitranslmed.3006294.
Background Scott G, Carhart-Harris RL. Psychedelics as a treatment for disorders of consciousness. Neurosci Conscious. 2019 Apr 21;2019(1):niz003. doi: 10.1093/nc/niz003. eCollection 2019.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	0.75 ug/ml	Intravenous

Indications

No indication recorded.